English
中文
CAS:84625-61-6
Appearance:White or light yellow powder
Storage:2-8℃
Purity:≥98.5%
Product Introduction:
Storage conditions: 2-8 ℃, avoid light, moisture, sealed and dry.
Use and synthesis method:
Scientific research reagent, widely used in molecular biology, pharmacology and other scientific research. The broad-spectrum antibacterial activity of itraconazole is independent of the mode of administration. Itraconazole inhibits fungal growth by inhibiting the synthesis of ergosterol, an essential component of fungal cell membrane. Under normal conditions, lanosterol, the precursor of ergosterol, undergoes 14α-demethylation catalyzed by fungal cytochrome P450. Itraconazole interacts with fungal CYP at the basal junction, blocking its demethylation and allowing lanosterol and 14α-methylsterol to accumulate on the cell membrane. Impaired ergosterol synthesis leads to changes in the permeability of fungal cell membrane, resulting in inhibition of enzyme activity and chitosan synthesis.
Itraconazole is indicated for the treatment of:
1: For systemic fungal infections such as aspergillosis, candidiasis, cryptococcosis (including cryptococcal meningitis), histiocytosis, sporotrichosis, Brazilian paraccidioidosis, blastomycosis and a variety of other rare systemic or tropical fungal diseases.
2: For oral cavity, pharynx (foreign data), esophagus (foreign data), vulvovaginal candida infection, as well as fungal conjunctivitis, fungal keratitis.
3: For superficial fungal infections, such as tinea pedis, tinea corporis, tinea corporis, tinea versicolor, etc.
3: It is used for onychomycosis caused by dermatophyton and (or) yeast.
Solubility:
Soluble in dichloromethane, slightly soluble in tetrahydrofuran, soluble in chloroform (50 mg/ml), DMF (~0.5 mg/ml), DMSO (50 mM), water (<1 mg/ml, 25℃), methanol or ethanol (10 mM, heated) almost insoluble
Note：Product information may be optimized and upgraded. Please refer to the actual label information for accuracy.
